Related Experiment Video

Updated: May 25, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Joan T Garrett1, Anindita Chakrabarty, Carlos L Arteaga

  • 1Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.

Oncotarget
|January 18, 2012
PubMed

Insights

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway in cancer requires combination therapies. Inhibiting compensatory feedback loops involving receptor tyrosine kinases (RTKs) is crucial for sustained therapeutic effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is crucial for cellular functions and frequently dysregulated in cancer.
  • Activation of the PI3K pathway in cancer occurs through genetic alterations like mutations, amplifications, and deletions.
  • The critical role of PI3K in oncogenesis has driven the development of targeted therapies.

Purpose of the Study:

  • To investigate the compensatory mechanisms that limit the efficacy of PI3K pathway inhibitors in cancer.
  • To propose combination strategies to overcome resistance to PI3K pathway-targeted therapies.
  • To enhance the clinical benefit of inhibiting the PI3K/AKT/mTOR axis in cancer treatment.

Main Methods:

  • Analysis of feedback reactivation of receptor tyrosine kinases (RTKs) upon PI3K pathway inhibition.
  • Evaluation of FOXO-dependent mechanisms in compensatory pathway activation.
  • In silico or experimental modeling of combination therapies targeting RTKs, PI3K, and mTOR.

Main Results:

  • Inhibition of the PI3K pathway triggers FOXO-dependent feedback reactivation of RTKs.
  • This reactivation limits sustained pathway inhibition and attenuates the efficacy of therapeutic agents.
  • Single-agent PI3K inhibitors demonstrate limited clinical activity due to these compensatory mechanisms.

Conclusions:

  • Combination therapies are necessary to overcome feedback reactivation and achieve sustained PI3K pathway inhibition in cancer.
  • Targeting RTKs, PI3K, and mTOR concurrently may be required to maximize clinical benefits.
  • This approach holds promise for improving outcomes in patients with PI3K-dependent cancers.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...